Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide once weekly versus placebo in adults with type 2 diabetes mellitus inadequately controlled with diet and exercise
2016-001857-42Phase 3Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Feb 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Efpeglenatide once weekly with Placebo once weekly (2 arms). Primary endpoint: Change in glycated hemoglobin (HbA1c) (%). Status: unknown.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001857-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001857-42.